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Abstract
Background—Determining the relationship between age and Alzheimer's disease (AD) 
presentation is important to improve understanding and provide better patient services.
Methods—We used AD patient data (N=7815) from the National Alzheimer Coordinating 
Center database and multinomial logistic regression to investigate presentation age and first 
cognitive / behavioral symptoms.
Results—The odds of having a non-memory first cognitive symptom (including impairment in 
judgment and problem solving, language and visuospatial function) increased with younger age 
(p<0.001, all tests). Compared with apathy/withdrawal, the odds of having depression, and “other” 
behavioral symptoms increased with younger age (p<0.02, both tests), whereas the odds of having 
psychosis and no behavioral symptom increased with older age (p<0.001, both tests).
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Conclusions—There is considerable heterogeneity in the first cognitive / behavioral symptoms 
experienced by AD patients. Proportions of these symptoms change with age with patients 
experiencing increasing non-memory cognitive symptoms and more behavioral symptoms at 
younger ages.
Keywords
Alzheimer's disease; clinical neurology history; first symptoms; cognition; behavior; 
neuropsychology; age
1. Introduction
The prototypical evolution of symptoms in Alzheimer's disease (AD) begins with episodic 
memory loss followed by impairment in other cognitive and behavioral domains [1, 2]. 
However, less typical, non-memory presentations of AD have been recognized and include 
patients with visuospatial dysfunction, visuoperceptual dysfunction, dyspraxia, executive 
dysfunction, literacy problems and language problems [1-6].
There is evidence from small studies that atypical AD presentations tend to occur at younger 
ages of onset [4, 7, 8] or are seen in high proportions in younger group studies [9]. Studies 
assessing the relationship between onset age and first symptoms often dichotomize subjects 
into early onset (before 65 years) or late onset disease (65 years and above). Such analyses 
have shown that around one-third of early onset AD subjects present with non-memory 
symptoms including apraxia and visuospatial dysfunction, aphasia and other language 
dysfunction, and agnosia [7]. Although the 65 year age cut-off can be useful, it is arbitrary 
and patterns of predominant first symptoms may vary more gradually with increasing age. 
An alternative analytical approach is to divide patients into groups based on 
neuropsychological profiles and assess between-group differences in demographics or other 
features including onset age [10] or brain atrophy phenotype [11, 12]. Although such studies 
have revealed differences in AD subgroups and demonstrate the underlying heterogeneity of 
AD features, many subjects tend to be excluded from such analyses as they fall outside these 
groups by exhibiting characteristics of neither or both. As such, groups defined in this way 
may be extremes on a continuum of disease presentations [9, 13, 14].
Since much of the research relating age to AD presentation is single-site or using relatively 
small sample sizes [4, 7-9], there is a need to demonstrate heterogeneity in larger, less-
selected multi-site patient samples to produce more precise estimates of age – AD 
presentation relationship. Further, those with early onset AD have been shown to have a 
longer disease duration prior to diagnosis [7, 15], likely in part due to misdiagnosis [16], 
making the understanding of the different presentations in AD and how these relate to age 
extremely important for improving services offered to younger patients.
The aim of this study was to assess the proportions of first predominant reported cognitive 
and behavioral symptom according to presentation age in a large, multi-site and unselected 
sample of patients with a clinical diagnosis of AD. We further assessed neuropsychological 
test performance to test the hypothesis that age influences psychometric impairments in a 
manner congruent with reported symptoms. Our hypotheses were that: 1) patients presenting 
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at younger ages were more likely to have a first symptom in a non-memory cognitive 
domain; 2) younger presenting patients were more likely to experience behavioral 
symptoms.
2. Methods
2.1. Subjects
We included subjects from the National Alzheimer's Coordinating Center (NACC) dataset 
(http://www.alz.washington.edu/). NACC developed and maintains a database of 
standardized clinical research data collected from 34 past and present NIA-funded 
Alzheimer's disease centres (ADC) from across the USA. NACC recruitment and data 
collection has been described previously [17, 18]. Data included patients seen at ADCs 
between January 2005 and June 2012. Subjects included in our study had to be demented 
and have a diagnosis of probable or possible AD according to standard diagnostic criteria at 
the first visit [19]. We generated subsets of this (total AD) group which excluded those with 
presence of any other major psychiatric or neurological disorder (AD no other cause) and 
which additionally excluded AD subjects with possible AD (probable AD no other cause) to 
investigate the robustness of findings.
The study was approved by an institutional review board at each institution. Written 
informed consent was obtained from all NACC participants and informants.
2.2. Main outcome measures
The outcome measures assessed were the following: (1) first reported predominant cognitive 
symptom which included categories: memory; judgment and problem solving; language; 
visuospatial function; attention/concentration; “other”; fluctuating cognition; no symptom 
and “unknown”. (2) first reported predominant behavioral symptom which included 
categories: apathy/withdrawal; depression; psychosis; disinhibition; irritability; agitation; 
personality change; “other”; REM sleep behaviour disorder; no symptom and “unknown”. 
Of note, the “no symptom” categories were recorded as “not applicable” by NACC. The 
symptom nominal variables were recorded by the clinician at the first visit. Specifically, the 
clinician is asked to indicate which predominant symptom was the first recognized as a 
decline in the subject’s cognition and behaviour. Only one cognitive and one behavioural 
symptom category was allowed per patient.
2.3. Neuropsychology
Cognitive functioning was assessed using a standardized neuropsychological battery [20] at 
the same visit as assessment of first predominant symptoms. Global cognitive functioning 
was measured using the mini-mental state examination (MMSE) [21]. From this test, copy 
of the pentagons was used as a measure of visuospatial functioning. For memory, we used 
logical memory story A, parts 1 and 2 from the Wechsler Memory Scale. Attention and 
working memory were measured using digit span forward and backward and processing 
speed by trail making test A and digit symbol from the Wechsler Adult Intelligence Scale 
(WAIS). Trail making test B was used to measure executive functioning. Fluency (animals 
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and vegetables) and the Boston Naming test were used as measures for language. The 
number of missing data points varied across tests.
2.4. Statistics
All analyses were performed in Stata SE (version 13). We calculated summary demographic 
statistics. We also calculated the proportions of the total AD group who had other 
psychiatric and neurological diagnoses and were excluded from the AD subsets. To 
investigate memory vs. non-memory complaints we dichotomized the first cognitive 
symptom as memory or non-memory for those subjects who reported a cognitive symptom 
(i.e. excluding the no symptom and “unknown” categories). This was used as the dependent 
variable in binary logistic regression models with age at first presentation as a continuous 
predictor variable.
We performed separate multinomial logistic regression analyses to assess the relationship of 
age at first presentation (predictor variable) with i) first predominant cognitive symptom and 
ii) first predominant behavioral symptom (dependent variables). In our main analyses we 
considered four age-bands, specifically <60, 60-69, 70-79 and >79 years. We took the oldest 
age group and the most commonly reported symptom (cognitive or behavioral) as the 
reference groups. In addition, tests for trend were carried out using models that treated age 
as a continuous, rather than a categorical, predictor. Symptom groups with fewer than 10 
subjects for any age group were excluded from all comparisons. For cognitive symptoms 
these excluded categories were attention/concentration, “other”, fluctuating cognition, no 
symptom, and “unknown”. For behavioral symptoms these were REM sleep disorders and 
“unknown”. All analyses were first performed in the total AD group, and then repeated in 
the AD subsets.
For graphical representation we created plots showing the proportions of first reported 
domains/symptoms by age-band. All symptoms, irrespective of group size are represented in 
these figures.
For each neuropsychological test we performed a linear regression analysis with age at first 
presentation/10 as a continuous predictor and test score as the outcome variable. Resultant 
coefficients represent a change in neuropsychological score for a 10 year increase in age of 
presentation. All analyses included gender and education as covariates and therefore patients 
without recorded educational attainment were excluded from these analyses. Floor (poorest 
possible performance) and ceiling (best possible performance) were reported where there 
were 10 or more subjects exhibiting these effects. Wald tests of the linear effect of the test 
score were performed. For the copy of the pentagons test, where the result was a binary 
score, the p value reported is that for this binary predictor. We additionally adjusted for the 
time between test parts I and II for the logical memory test part II. Semi-partial R2 values 
were derived for the relationship between age and test scores.
Analysis of demographic and genetic variables by first predominant cognitive and 
behavioral symptom is presented in the Supplementary Section and Supplementary table 4.
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3. Results
3.1 Demographics
Summary demographic information is shown in table 1. On average, patients were 75 years 
old when they first presented at the AD Center for their NACC visit but this ranged from 36 
to 110 years. More than half of the patients were female. At first presentation, patients were 
mildly to moderately demented (mean (SD) MMSE 19.3 (6.8)). Demographic results were 
similar in the total sample and the subsets. The proportions of the total AD group with 
another psychiatric or neurological diagnosis are displayed in supplementary table 1.
3.2. First predominant cognitive and behavioral symptom
The most commonly reported first predominant cognitive symptom was memory (see figure 
1). For those who reported a first cognitive symptom the proportion of AD patients with a 
non-memory first predominant cognitive symptom gradually decreased with increasing age: 
<60 years 26.1%, 60-69 years 19.8%, 70-79 years 10.5%, >79 years 6.3%. In a logistic 
regression analysis combining all non-memory cognitive symptom domains the odds of a 
non-memory first predominant symptom was multiplied by 1.72 (95% CI 1.61, 1.84, 
p<0.001) for each ten year decrease in age. Table 2 shows more detailed results from the 
multinomial logistic regression analyses that distinguished results for the non-memory 
symptom domains. Compared with memory, the odds of having judgment and problem 
solving, language and visuospatial problems as the first predominant cognitive symptom all 
increased with younger presentation age. These results remained largely unchanged when 
analyses were restricted to the AD subsets (see supplementary tables 2 and 3).
The most commonly reported first behavioral symptom was apathy/withdrawal (see table 2 
and figure 2). Overall, compared with apathy/withdrawal, the odds of having depression and 
“other” behavioral symptoms increased with younger presentation age. By contrast, the odds 
of having psychosis and no reported symptom increased with older presentation age. 
Notably, the significant behavioral findings were typically smaller in magnitude than those 
seen between presentation age and cognitive symptoms. These behavioral symptom results 
remain largely unchanged when analysis was restricted to the two AD subgroups (see 
supplementary tables 2 and 3).
3.3 Neuropsychological results
Results from linear regression analyses relating age at presentation to performance on 
neuropsychological tests are shown in Table 3. The table presents the effect of ten year 
increases in age on test score adjusted for gender and education. Results showed that older 
age at presentation was associated with poorer scores on logical memory tests, trails making 
tests A and B, digit symbol, category fluency and Boston Naming Test. For example a ten 
year increase in age at presentation was associated with a 0.11 (95% CI 0.02, 0.20) lower 
logical memory test score. By contrast younger ages of presentation were associated with 
reduced ability to copy pentagons and shorter digit spans.
Barnes et al. Page 5
Alzheimers Dement. Author manuscript; available in PMC 2016 November 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
4. Discussion
This study showed that non-memory first symptoms including judgment and problem 
solving, language, and visuospatial problems increased gradually with younger presentation 
of AD. This is evidenced by higher odds ratios of these non-memory symptoms compared 
with memory symptoms in the younger age bands vs. the oldest age band. In addition, 
younger patients were more likely than older patients to have a behavioral symptom. 
Relative to having apathy/withdrawal, depression and “other” behavioral symptoms 
increased with younger presentation (higher odds ratios in younger age bands compared 
with oldest), whereas psychosis increased with older presentation (lower odds ratios in 
younger age bands compared with oldest). Odds ratios were generally higher for the 
cognitive symptoms than behavioral symptoms and showed clearer increases per lower age 
band for the non-memory cognitive symptoms.
We show that 74% of AD patients presenting at <60 years had a predominant first symptom 
of memory problems compared with 92% in those 70 years or over. The proportions of 
memory vs. non-memory first symptoms are similar to that of previous studies: one study 
reported that 68% of cases under 65 years at onset age had a memory presentation compared 
with 94% in cases 65 years and above [7]; another reported that 63% of AD patients with 
onset <60 years had a memory presentation [22]. In another single-site study where the 
average onset was around 60 years, 79% of cases had typical AD, mild memory problems or 
an amnestic syndrome as opposed to other focal AD types [9] which is again in keeping with 
our findings.
Our data also give weight to smaller neuropsychological studies which have shown that 
earlier onsets of AD are associated with more fronto-parietal and less temporal lobe 
dysfunction [23]. Our result of a greater proportion of early visuospatial dysfunction at 
younger ages (7% under 60 years vs. 1% 70 years and above) replicates other smaller 
studies which have shown the average age of those presenting with visual AD subtypes was 
below 65 years [7-9]. In terms of proportions, one study found that combined apraxia/
visuospatial dysfunction made up 12% of younger onset cases (< 65 years onset) [7], which 
is higher than our 7%; unfortunately, apraxia is not recorded by NACC. Much like our 
analyses, that study also demonstrated higher proportions of language presentations at 
younger onset (9% [7], similar to our 7%). Our study demonstrates that age cut-offs used in 
research are arbitrary as non-memory presentations increase with decreasing age.
Our data show that some older AD patients do not have a first symptom of memory 
dysfunction (8% of 70+ year olds). Heterogeneity in AD presentations has previously been 
shown in a selected subset of NACC data with a study demonstrating dysexecutive and 
amnestic syndromes with the average age of these groups being greater than 70 years [10]. 
Taken together these findings demonstrate AD heterogeneity remains at older ages, a finding 
further substantiated by phenotype clustering in AD subjects over 60 years [24] as well as in 
selected cohorts such as the Alzheimer's Disease Neuroimaging Initiative [25].
Motivation for behavioral symptom research in dementia has increased recently [26, 27]. 
The majority of AD patients in our study had a behavioral symptom which is similar, but 
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lower in proportion, to another study which reported around 90% of AD patients having 
behavioral/psychological symptoms [28]. The highest proportions of symptoms in our study 
were apathy/withdrawal, depression and irritability which are similar findings to other 
studies with respect to analogous symptom categories: one study found apathy, depression 
and agitation to be the most frequently reported in late onset AD [29] and another found 
apathy, irritability and agitation to be most commonly reported in young onset AD and 
depression, apathy, irritability and anxiety in late onset AD [30]. We found an increase in 
psychosis with age, however, a review of previous studies found the relationship of age and 
psychosis to be equivocal [31].
In terms of neuropsychology tests we found that older presenting subjects were more 
impaired with respect to memory scores (logical memory parts I and II), processing speed 
(trail making A, digit symbol), executive functioning (trail making B) and language (animals 
and vegetables and Boston naming test). Younger presenting patients had more problems 
with attention and working memory (digit span forwards and backwards) and visuospatial 
function (pentagons). Despite the fact that language problems as a first symptom were 
associated with younger presentation of AD patients, the neuropsychology revealed that 
older subjects were more impaired with respect to language at first visit. This may be due to 
the accrual of more language deficits by first visit in older patients and/or due to the 
difference in nature between a symptom variable (perception of a problem) and a 
neuropsychological test score (relatively objective assessment of one aspect of function).
Our findings are in keeping with others who have assessed identical or modified 
neuropsychological tests and their relationships with onset age. Greater language problems 
with older onsets have been previously shown (Boston naming test, [32]). Others have 
demonstrated that those with younger onset have shorter digit spans [33-35] and poorer 
performance drawing pentagons [36]. Our results differ from that of two studies which 
found no significant differences between older or younger onset cases in any 
neuropsychological test performed in their study including language, visuospatial and 
attention tasks [37, 38]. However, both of these studies were performed using smaller 
sample sizes, potentially limiting the power to detect differences. Using identical tests to our 
own, one study has shown that processing speed and executive function was worse in 
younger subjects (trails A and B [35]) whereas we found older patients performed more 
poorly in these tests. Studies investigating onset age in AD and neuropsychological features 
span the past three decades and therefore differences between studies’ findings may derive 
from improved diagnostic criteria [35] as well as differing disease severities of the 
populations, power to detect differences, and covariates used in analyses. Although we have 
demonstrated significant relationships between presentation age and neuropsychology, the 
amount of variance in test scores explained by age was low, with the highest value being for 
the Boston Naming Test for which age explained 3% of the variance.
The findings of our study are congruent with those investigating the relationship between 
age and brain morphology and pathology. One autopsy study has demonstrated that 
hippocampal sparing AD cases (suggestive of a non-memory presentation) were, on average, 
younger at onset than typical cases [39] and imaging studies have demonstrated relative 
preservation of the hippocampus/ medial temporal lobe at younger onsets [40-42]. Although 
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the aging process affects widespread cortical areas including the temporal lobe [43, 44], the 
areas disproportionately affected by AD and aging processes differ with temporal areas 
more affected by AD and fusiform, caudal insula and medial frontal regions more affected 
by aging [45]. Therefore, our finding of a higher proportion of memory (temporal lobe) AD 
cases with age is partially congruous with the pattern of age-related changes that can occur. 
Arguably however, aging in addition to AD would potentially lead to more non-memory 
cases occurring at older ages (such as frontal cases) if age-related differences in AD were 
driven by a normal aging process applied to a uniform AD process. It is more likely that the 
differences we observe in terms of symptoms and age relate in part to predominance of e4 in 
memory cases; e4 is an important risk factor for later onset AD [6] and has been shown to 
drive atrophy to the medial temporal lobe [46, 47]. Other unknown factors, which cause 
atrophy outside of the temporal lobe, non-memory deficits and symptoms, and younger 
onsets, are also likely to influence our findings.
The strengths of this study are the large sample size and systematic data collection which 
enables more fine-grained analyses of the effects of age on first predominant symptoms. The 
multi-site nature of the study improves generalizability of results as compared with single-
site studies.
One limitation of this study is the likely noise associated with large cohorts of unselected 
data; our results may be in part caused by misdiagnoses, particularly in the non-memory 
subtypes, as we did not assess autopsy-confirmed cases. Clinical diagnosis of AD has been 
shown to be incorrect in 7%-13% of cases investigated at post mortem [48-50]. Notably, a 
clinical diagnosis of probable AD in the NACC neuropathological cohort was shown to have 
a sensitivity and specificity of 71% compared with a pathological diagnosis [51]. Biomarker 
support for AD diagnosis will be an increasingly important tool in the clinical management 
of young onset disease where diagnostic accuracy may be lower. As biomarkers are 
increasingly used in practice and their interpretations improve, it may be that diagnostic 
accuracy increases with time which will be important to consider in studies where data 
collection spans many years. In our study, we performed additional analyses in increasingly 
restrictive subsets to minimize the chances of misdiagnoses influencing results. Results 
remained largely unaltered, illustrating that symptom heterogeneity is likely to exist in AD. 
The patients in our study were from the USA and therefore cultural differences may limit the 
generalizability of our results. These differences may manifest in terms of stigma associated 
with dementia, when to present to clinic, and the relative importance of specific symptoms. 
Despite possible differences, we found similar results to that of European studies which 
have showed an increased predominance of non-memory cognitive symptoms at younger 
onsets [7, 9]. We chose to investigate presentation age rather than age of cognitive decline 
which differs from most studies in the literature. This was chosen as it was more likely to be 
accurately recorded, was available in more subjects than age of decline, and our findings are 
likely to be more relevant to physicians in clinic. Finally, we cannot exclude the possibility 
that the first symptoms experienced by AD patients in this study are in part due to normal 
aging. Adjustment of our results for those found in controls is not possible using NACC data 
since symptoms are not routinely recorded for controls. Further since a proportion of elderly 
controls are likely to have underlying AD pathology [52-54], or other neurological 
conditions, adjustment for a “normal” aging process is difficult.
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A further weakness is the recruitment bias that is likely to be present in this data collection: 
NACC data is derived from academic centers which are more likely to have complex and 
atypical cases limiting generalizability to community-based patients. Further, subjects had to 
have a diagnosis of AD according to NINCDS-ADRDA criteria which requires memory 
impairment. This means that early presenting non-memory AD patients may have been 
excluded leading to an underestimate in their proportions. Finally, the neuropsychology tests 
performed do not fully investigate non-memory domains. For example, the pentagon copy 
test was the only visuospatial neuropsychological examination; this test is not a 
sophisticated or detailed investigation of such deficits. Similarly, the language tests used 
may not fully investigate deficits present in younger onset cases. Incorporating more non-
memory tests into neuropsychological batteries is important, especially if younger 
presenting patients attend clinic.
We conclude that presentation age influences first symptoms experienced by clinically-
diagnosed AD patients. Although memory problems are the most common first cognitive 
symptom experienced at any age, non-memory symptoms including judgment and problem 
solving, language, and visuospatial problems are more prevalent in younger patients. The 
largest proportion of AD subjects had apathy/withdrawal as first reported behavioral 
symptom. Compared with apathy/withdrawal, depression, and “other” behavioral symptoms 
increased with younger presentation ages whereas older subjects were more likely to have 
psychosis or no behavioral symptom. Importantly, nonamnestic presentations are 
acknowledged and behavior is included in the new AD diagnostic criteria [2]. Appreciation 
that non-memory first symptoms occur in AD, particularly in younger cases, is important so 
that patients have a less tortuous route to diagnosis. Further, non-memory 
neuropsychological tests are needed to evaluate the full range of deficits experienced. Better 
awareness of non-memory symptoms and more comprehensive testing would allow for 
improved services for patients: for example the development of appropriate information 
materials for those with visuospatial problems and support services for those who 
experience behavioural symptoms.
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Research in context
Systematic review: we sought articles which included terms “Early Onset Alzheimer*” or 
“Young Onset Alzheimer*” using PubMed. We assessed articles which described age of 
clinical presentation or onset and first symptoms experienced by the AD patient.
Interpretation: The findings from our study are from the largest sample of AD subjects 
reported (n>7000). Our cohort is relatively unselected, only requiring patients to be 
demented and have a diagnosis of possible or probable AD. The large sample size allows 
for a more fine-grained and precise analysis of the relationship between age and first 
symptoms in AD than has been possible to date.
Future directions: The patients included in this study are from academic centers across 
the USA. Therefore subjects referred to these centers may be more unusual and complex 
AD cases. Extending this research question into large community-based datasets would 
give researchers more insight into whether the findings of this present study hold for a 
potentially different population of AD patients.
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Figure 1. Age at first presentation and first predominant cognitive symptom
Percentages are given above colored bars for each symptom group where ≥ 2%
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Figure 2. Age at first presentation and first predominant behavioral symptom
Percentages are given above colored bars for each symptom group where ≥ 2%
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Table 1
Demographic information for the total AD group and subsets.
Total AD AD no other cause Probable AD no other cause
N 7815 4644 4350
Age at first presentation 75.5 (9.7) [36-110] 75.7 (9.6) [36-110] 75.7 (9.5) [36-102]
Gender, % women 56.2 56.2 56.6
Probable AD, as % of probable and possible AD 82.6 93.7 100.0
Symptom length, yearsa 5.0 (3.5) 5.0 (3.5) 5.1 (3.5)
Education, yearsb 13.8 (3.9) 14.0 (3.8) 14.0 (3.8)
MMSE at first presentation /30c 19.3 (6.8) 19.3 (6.8) 19.3 (6.8)
Global CDR, % scoring 0, 0.5, 1, 2 and 3 0.2, 28.0, 45.1, 17.5, 9.3 0.0, 29.1, 44.9, 17.0, 9.0 0.0, 28.4, 45.5, 17.1, 8.9
CDR Sum of Boxes, /18 7.0 (4.5) 7.0 (4.4) 7.0 (4.4)
APOE e4 % 0,1,2 allelesd 42.4, 45.4, 12.3 40.2, 46.9, 12.9 39.4, 47.4, 13.2
Positive for APP, PS1, PS2, n 2, 13, 0 0, 8, 0 0, 8, 0
Mean (SD) and [minimum, maximum] values are shown unless otherwise stated
Data available in all subjects apart from
a
available in 7674 Total AD, 4559 AD no other cause, and 4272 Probable AD no other cause
b
available in 7750 Total AD, 4605 AD no other cause, and 4316 Probable AD no other cause
c
available in 7328 Total AD, 4353 AD no other cause, and 4091 Probable AD no other cause
d
available in 5218 Total AD, 3200 AD no other cause, and 3003 Probable AD no other cause
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